Petmed Express INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
PetMed Express, Inc. has filed its 2026 Proxy Statement, outlining director elections, executive compensation, and a proposal to increase shares under its 2024 Omnibus Incentive Plan.
NASDAQ
PetMed Express, Inc. announces its 2026 Annual Meeting of Shareholders to elect directors, approve executive compensation, and ratify a new independent auditor, Baker Tilly US, LLP, following the dismissal of RSM US LLP due to material weaknesses in internal controls.
NASDAQ
PetMed Express files an amendment to its definitive proxy statement to correct information in the Pay versus Performance Table regarding Other NEOs' compensation for fiscal years 2022 and 2021.
NASDAQ
PetMed Express, Inc. has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.
NASDAQ
PetMed Express is asking shareholders to approve a new omnibus incentive plan to attract and retain key personnel.